Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Etoposide (Primary)
- Indications Brain metastases; Small cell lung cancer
- Focus Therapeutic Use
- 15 Feb 2024 Status changed from active, no longer recruiting to discontinued.
- 10 Oct 2022 Planned End Date changed from 1 May 2024 to 30 Sep 2023.
- 10 Oct 2022 Status changed from recruiting to active, no longer recruiting.